NEW YORK (GenomeWeb News) – Myriad Genetics' investment into RainDance Technologies totals $5.0 million, the Salt Lake City-based company said in its Form 10-Q filed with the US Securities and Exchange Commission this week.
Registering provides access to this and other free content.
Already have an account?Login Now.
This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.
Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.
Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.
A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.